This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Elizabeth N. Allred, MD; Olaf Dammann, MD; Karl K. C. Kuban, MS, SM; Alan Leviton, MD, SM; Marcello Pagano, PhD; Jane E. Stewart, MD, SM; Linda J. VanMarter, MD, MPH
Children's Hospital Boston, Mass

JAMA. 1997;277(13):1033.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Dr Schendel and colleagues¹ may have more methodologic limitations than the authors acknowledge. Perhaps the major limitation is the failure to recognize that magnesium might be a marker for other phenomena that contribute to reduced risk of cerebral palsy.

During the years study subjects were born (1986-1988), magnesium sulfate was not used as a first-line tocolytic. From 1984 through 1987,31% of the 90 women in one Boston, Mass, hospital who received magnesium sulfate just prior to the birth of a very low-birth-weight infant had a diagnosis of pregnancy-induced hypertension or preeclampsia recorded in the hospital chart,² similar to the experience in Atlanta, Ga reported by Schendel et al.¹ On interview, however, approximately 31% of these women acknowledged that they were told they had either preeclampsia or hypertension.

If the situation in Atlanta mimicked what we found in Boston, then receipt of . . . [Full Text PDF of this Article]

Footnotes
Edited by Margaret A. Winker, MD, Senior Editor, and Phil B. Fontanarosa, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?